The market for bispecific antibodies in oncology is expected to witness significant expansion in the near future. This growth is fueled by the increasing prevalence of diseases such as Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Non-Small Cell Lung Cancer (NSCLC), Biliary Tract Cancer (BTC), among others. Factors contributing to this growth include technological progressions, rising regulatory clearances, strategic partnerships, and more. This market is forecasted to see substantial growth in revenue and adoption rates as the demand for innovative oncology treatments continues to rise.